If DNA-design software is going to become normal developer tooling, I think it should lint sequences locally before they ever reach a synthesis provider. That would give researchers a privacy boundary around proprietary designs, unpublished work, and identifying metadata—not a guarantee of safety, but a useful first check. IBBIS’s open-source Common Mechanism suggests this is technically feasible with local reference databases and multiple search modes.
The uncomfortable trade-off is that centralized providers may have better-curated intelligence, fresher updates, customer verification, and human follow-up. A transparent community ruleset could be audited, versioned, and distributed with signed database updates, but it could also become stale or easier to evade. The HHS framework itself recognizes both privacy-preserving screening and the need for evolving threat information.
Would local linting plus mandatory provider screening be the right compromise? I’d like to hear implementation models, failure cases, or reasons cloud-only screening is safer.